AAPP 2026 industry supported showcases (non-continuing education) are programs developed for educational purposes, designed for the psychiatric pharmacist, and are included in participant registration fees.
A few reminders to attendees:
- Badge scanning:
- Your badge may be scanned upon entry. The scan only captures name, credentials, city, and state.
- Noise courtesy:
- We appreciate you keeping noise to a minimum during sessions.
- Recording notice:
- All events are live-streamed and recorded.
- Seating guidance:
- Fill the room from front to back.
- Do not sit at tables with reserved signs.
- Meal information:
- All industry events feature a meal or refreshment break provided by AAPP.
- Meals/refreshments are served 15 minutes before the session start time, inside or directly outside of Regency Ballroom (Level 2).
- Meals are limited and will be served at tables only.
- A limited number of vegetarian/vegan/gluten-free meals are available. If desired, please inform the server upon taking a seat.
- To minimize noise, plates will not be removed after programming begins.
Program on Sunday, April 19 |
A Critical Moment in Schizophrenia Care: The Inpatient Opportunity
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Overview: Don’t miss this opportunity to learn about a different treatment option for adults with schizophrenia. Discover its clinical profile as well as practical considerations for an inpatient setting. The program also highlights unmet needs in the treatment of schizophrenia.
Learning Objectives
- Understand the impact and underlying pathophysiology of the full spectrum of schizophrenia symptoms
- Review the short- and long-term data supporting the efficacy, safety, and tolerability profile of COBENFY
- Review practical considerations when prescribing COBENFY
Faculty
 | Jacob Hanaie, PharmD, APh Adjunct Assistant Professor, Keck School of Medicine of the University of Southern California Preceptor, Keck School of Medicine of the University of Southern California Director of Pharmacy, Kedren Acute Psychiatric Hospital |
Supported by
 | Programs on Monday, April 20 |
Tardive Dyskinesia: Considerations in the Specialty Pharmacy Setting
Breakfast will be served from 7:00-7:15 AM Pacific, immediately before the program.
Overview: This presentation will review TD treatment approaches, highlighting the crucial differences between appropriate treatment and the common, yet inappropriate, use of anticholinergics for TD, and emphasizing considerations for patients taking multiple medications. The role of AUSTEDO XR, an FDA-approved treatment option, will also be reviewed, with a focus on its metabolic profile which allows for few restrictions related to drug-drug interactions.
Learning Objectives
- Review TD treatment approaches
- Highlight differences between appropriate and common use of anticholinergics
- Review role of AUSTEDO XR metabolic profile
Faculty
 | Hany Mohamed, PharmD, RPh, BCGP, BCPP Director of Clinical Services, LI Script LLC Key Opinion Leader and LTC Pharmacy Consultant |
Supported by
Industry Showcase | Supported by AbbVie
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Overview: To be announced
Learning Objectives: To be announced
Faculty
 | Gregory W. Mattingly, MD Psychiatrist President, St. Charles Psychiatric Associates President and Principal Investigator, Midwest Research Group President, American Professional Society for ADHD and Related Disorders Associate Clinical Professor, Department of Psychiatry, Washington University School of Medicine |
Supported by
The Role of UZEDY in Schizophrenia Treatment: A Clinical Perspective
Refreshment break will be served from 4:30-4:50 PM Pacific, immediately before the program and to permit time for attendees to navigate from prior programming sessions to the Regency Ballroom (Level2).
Overview: This presentation will delve into the potential consequences of schizophrenia relapse and highlight the role of long-acting injectables in schizophrenia treatment. Attendees will gain insight into the potential clinical impact of UZEDY through select clinical trial data. Additionally, the session will enhance understanding of the features of UZEDY and its potential role in schizophrenia treatment.
Learning Objectives
- Review potential consequences of schizophrenia relapse
- Highlight the role of long-acting injectables in schizophrenia treatment
- Provide insight to the potential clinical impact of UZEDY through clinical trial data
Faculty
| Jacob Hanaie, PharmD, APh Adjunct Assistant Professor, Keck School of Medicine of the University of Southern California Preceptor, Keck School of Medicine of the University of Southern California Director of Pharmacy, Kedren Acute Psychiatric Hospital |
Supported by
Program on Tuesday, April 21 |
Challenges in Achieving Symptom Control in Major Depressive Disorder: Considering Adjunctive Treatment Options
Lunch will be served from 11:00-11:15 AM Pacific, immediately before the program.
Overview: This session examines the importance of addressing inadequate response in patients with major depressive disorder to optimize symptom control. We will review treatment challenges, discuss integrating an adjunctive atypical antipsychotic with antidepressant therapy, and examine data on efficacy and safety to support individualized treatment planning.
Learning Objectives
- Consider how delays in MDD treatment affect patients' well-being and the importance of earlier treatment intervention
- Recognize the benefit of earlier intervention with atypical antipsychotics and when to adjust treatment
- Examine the clinical trial data for a new adjunctive treatment option for adult patients with MDD
Faculty:
Allen D. Bott, MD
Adult and Child Neurology
Supported by
